Shares of biotech Immunomedics (NASDAQ: IMMU) skyrocketed 125% in April, according to data from S&P Global Market Intelligence. The FDA declined to approve the company's TNBC drug in January 2019 because of issues at the manufacturing plant where it was to be produced.

Q1 2020 Immunomedics Inc Earnings Call

Is (IMMU) Outperforming Other Medical Stocks This Year?

Live audio webcast of the fireside chat will be accessible and available for replay from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in virtual one-on-one meetings with institutional investors. Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.

Immunomedics, Inc. (NASDAQ:IMMU) shareholders will have a reason to smile today, with the analysts making substantial...

Immunomedics (IMMU) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

* Insider buying can be an encouraging signal for potential investors. * A couple of biotech stocks saw some notable insider buying last week. * Some of these insiders made return trips to the buy window.Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty.Insiders continued to add shares despite overall market volatility and global economic gloom. Here are some of the most noteworthy insider purchases reported in the past week.Immunomedics An Immunomedics, Inc. (NASDAQ: IMMU) director took advantage of a common stock offering to add 1.75 million shares. At the offering price of $28.50 per share, that cost the director almost $49.88 million and raised the stake to 26.25 million shares. Shares outstanding number fewer and 180 million.Immunomedics stock ended last week's trading at $30.38 per share, so the purchase seems well timed. The share price is up more than 157% since its year-to-date low last month.See Also: Elon Musk Says Tesla's Stock Price Is Too High, Tweets About Freedom, Gene Wilder And MoreMyovant Sciences Myovant Sciences Ltd (NYSE: MYOV) saw 10% owner Sumitomo Chemical purchase about 190,500 shares of this London-based biopharmaceutical company last week at prices averaging about $12.05 apiece. That totaled almost $2.30 million. Note that Myovant's parent is a subsidiary of Sumitomo, which frequently has been buying shares since establishing a Rule 10b5-1 stock trading plan during the market's pandemic selling panic in mid-March.Myovant stock ended the week trading at $11.15, below the above purchase price. However, shares are still up more than 68% from their year-to-date low in March.Simply Good Foods A director at Simply Good Foods Co (NASDAQ: SMPL) returned to the buy window last week. That director bought more than 87,800 shares at prices ranging from $16.76 to $17.00, totaling over $1.48 million. The director and seven others were purchasing shares throughout April.Simply Good Foods stock popped more than 3% in the past week and closed most recently at $18.35 a share. That is well above the director's latest purchase price range.Cincinnati Financial A pair of Cincinnati Financial Corporation (NASDAQ: CINF) directors shelled out $72.25 to $72.51 per share for 5,500 shares altogether of this property casualty insurance provider. That cost them more than $398,200, and it came in the wake of posting earnings that fell short of Wall Street expectations.The latest close at $60.95 per share is well below the purchase price range above, and it came after the shares hit a 52-week low of $60.00 on Friday. The stock is down about 42% year to date, while the S&P 500 is less than 10% lower.In addition, note that there was some amount of insider buying at AGNC Investment Corp (NASDAQ: AGNC), Sterling Bancorp (NYSE: STL) and Webster Financial Corporation (NYSE: WBS) last week as well.Keep up with all the latest breaking news and trading ideas by following Benzinga on Twitter.See more from Benzinga * Notable Insider Buys Of The Past Week: JPMorgan, Huntington Ingalls And More * Notable Insider Buys In The Past Week: Carnival, MGM And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

The Company announces that, after careful consideration, Harout Semerjian has decided to step down from his role as President and Chief Executive Officer (CEO) of Immunomedics. Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics, will continue to support the Company in an executive leadership role going forward. Patient enrollment into the Phase 3 TROPiCS-02 study of Trodelvy in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, has been resumed at approximately 20 clinical sites as of mid-May, with additional sites continuing to open in the coming weeks.

Ultragenyx (RARE) reports wider-than-expected first-quarter 2020 loss.

Breakouts beyond key levels of resistance suggest that the bulls are in control of the momentum in the biotech sector.

Immunomedics (IMMU) reports a narrower-than-expected Q1 loss. The focus is on its recently approved drug, Trodelvy, for mTNBC.

The total number of shares of common stock sold was 16,947,389, composed of 14,736,860 shares of common stock initially offered and an additional 2,210,529 shares of common stock sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, in each case at a public offering price of $28.50 per share. The total net proceeds from the offering are estimated to be approximately $459 million, after deducting underwriting discounts and commissions but before deducting other estimated offering expenses payable by the Company. Immunomedics intends to use the net proceeds from this offering primarily to support the commercial launch of Trodelvy™ in the United States in metastatic triple-negative breast cancer, continue to expand the clinical development programs for Trodelvy, invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), continued scale-up of manufacturing and manufacturing process improvements, as well as for working capital and general corporate purposes.

Spectrum Pharma (SPPI) misses bottom-line estimates for the first quarter and records no revenues.

In TROPHY U-01 cohort 2, at a median follow-up of 6.8 months, Trodelvy produced an objective response rate (ORR) of 29 percent (95% confidence interval [CI], 12–54) in 21 patients with mUC who were platinum ineligible and had progressed after prior checkpoint inhibitor (CPI) therapy, which is consistent with the 29 percent observed in the interim results from TROPHY U-01 cohort 1 of 35 mUC patients who were previously exposed to platinum-based and CPI therapies. Preclinical studies have shown Trodelvy to have activity against chemotherapy-resistant EC and significant bystander effect against EC with heterogenous Trop-2 expression.1 To evaluate this activity clinically, mEC patients who progressed after more than one prior systemic therapy were enrolled into a Phase 1/2 single-arm basket study.

Image source: The Motley Fool. Immunomedics Inc (NASDAQ: IMMU)Q1 2020 Earnings CallMay 6, 2020, 5:00 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood afternoon, ladies and gentlemen, thank you for standing by.

The conference call will be webcast via the Investors page on the Company’s website at https://immunomedics.com/investors/. Approximately two hours following the live event, a webcast replay of the conference call will be available on the Company’s website for approximately 30 days. Immunomedics is a leader in next-generation antibody-drug conjugate (ADC) technology, committed to help transform the lives of people with hard-to-treat cancers.

Please refer to the Company’s Quarterly Report on Form 10-Q for more details on the Company’s financial results. As the world responds to the outbreak of COVID-19, the thoughts of the Immunomedics team are with those affected, the staff who are providing essential services and healthcare workers fighting at the front lines of this pandemic.

As many are forced to stay at home due to the coronavirus, Immunomedics is using virtual tools to introduce doctors to its new breast cancer treatment, Trodelvy. Dr. Behzad Aghazadeh, Immunomedics Executive Chairman joins Yahoo Finance to discuss.

Trodelvy is the first anti-Trop-2 ADC recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. “We are excited to have Trodelvy rapidly available upon FDA approval, an important first step in our drive to gain brand awareness and adoption by healthcare providers,” said Brendan Delaney, Chief Commercial Officer of Immunomedics.

As of late, it has definitely been a great time to be an investor in Immunomedics, Inc. (IMMU).